Ulrike Nitz1,2, Oleg Gluz1,2,3, Michael Clemens4, Wolfram Malter3, Toralf Reimer5, Benno Nuding6, Bahriye Aktas7,8, Andrea Stefek9, Anke Pollmanns10, Fatemeh Lorenz-Salehi11, Christoph Uleer12, Petra Krabisch13, Sherko Kuemmel14, Cornelia Liedtke1,15, Steven Shak16, Rachel Wuerstlein1,17, Matthias Christgen18, Ronald E Kates1, Hans H Kreipe18, Nadia Harbeck1,17. 1. 1 West German Study Group, Mönchengladbach, Germany. 2. 2 Evangelical Hospital Bethesda, Mönchengladbach, Germany. 3. 3 University of Cologne, Cologne, Germany. 4. 4 Mutterhaus der Borromäerinnen, Trier, Germany. 5. 5 Clinics Suedstadt, Rostock, Germany. 6. 6 Evangelical Hospital Bergisch Gladbach, Bergisch Gladbach, Germany. 7. 7 University Clinics Essen, Essen, Germany. 8. 8 University of Leipzig, Leipzig, Germany. 9. 9 Johanniter-Krankenhaus Genthin-Stendal Hospitals, Stendal, Germany. 10. 10 Protestant Hospital Oberhausen, Oberhausen, Germany. 11. 11 Horst-Schmidt-Kliniken, Wiesbaden, Germany. 12. 12 Gynecological-Oncological Practice, Hildesheim, Germany. 13. 13 City Hospital, Chemnitz, Germany. 14. 14 Clinics Essen-Mitte, Essen, Germany. 15. 15 Unversity Hospital Charite, Berlin, Germany. 16. 16 Genomic Health, Redwood City, CA. 17. 17 University of Munich, Munich, Germany. 18. 18 Hannover Medical School, Hanover, Germany.
Abstract
PURPOSE: The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS: Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)90/cyclophoshamide (C)600 followed by four cycles of docetaxel (T)100 or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULTS: Of the 3,198 registered patients, 348 (RS ≤ 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v 60.8%; pN0, 58.2% v 59.5%; pT1, 57.6% v 52.3%; HR positive, 81.4% v 82.2%; RS greater than 25 [in HR-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v 89.9% [95% CI, 88.1% to 91.8%]; OS, 94.5% [95% CI, 93.1% to 95.9%] v 94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), despite a trend toward more-severe adverse events in the latter. Interaction analysis revealed no predictive trends with respect to key factors, including triple-negative, luminal A/B-like, pN, age, and RS status. CONCLUSION: In the West German Study Group PlanB trial, 5-year outcomes for TC and EC-T were equally excellent. Six cycles of TC is an effective/safe option in human epidermal growth factor receptor 2-negative EBC with pN0 high genomic risk or pN1 EBC with genomically intermediate- to high-risk disease.
RCT Entities:
PURPOSE: The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of humanepidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS: Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)90/cyclophoshamide (C)600 followed by four cycles of docetaxel (T)100 or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULTS: Of the 3,198 registered patients, 348 (RS ≤ 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v 60.8%; pN0, 58.2% v 59.5%; pT1, 57.6% v 52.3%; HR positive, 81.4% v 82.2%; RS greater than 25 [in HR-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v 89.9% [95% CI, 88.1% to 91.8%]; OS, 94.5% [95% CI, 93.1% to 95.9%] v 94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), despite a trend toward more-severe adverse events in the latter. Interaction analysis revealed no predictive trends with respect to key factors, including triple-negative, luminal A/B-like, pN, age, and RS status. CONCLUSION: In the West German Study Group PlanB trial, 5-year outcomes for TC and EC-T were equally excellent. Six cycles of TC is an effective/safe option in humanepidermal growth factor receptor 2-negative EBC with pN0 high genomic risk or pN1EBC with genomically intermediate- to high-risk disease.
Authors: Diana Lüftner; Ingo Bauerfeind; Michael Braun; Sara Y Brucker; Peter A Fasching; Ricardo Felberbaum; Friederike Hagemann; Renate Haidinger; Nadia Harbeck; Arnd Hönig; Jens Huober; Christian Jackisch; Hans-Christian Kolberg; Cornelia Kolberg-Liedtke; Thorsten Kühn; Nicolai Maass; Toralf Reimer; Andreas Schneeweiss; Eva Schumacher-Wulf; Florian Schütz; Christoph Thomssen; Michael Untch; Rachel Wuerstlein; Marc Thill Journal: Breast Care (Basel) Date: 2019-09-17 Impact factor: 2.860
Authors: Marija Balic; Christoph Thomssen; Rachel Würstlein; Michael Gnant; Nadia Harbeck Journal: Breast Care (Basel) Date: 2019-04-04 Impact factor: 2.860
Authors: Suzette Delaloge; Martine Piccart; Emiel Rutgers; Saskia Litière; Laura J van 't Veer; Franchette van den Berkmortel; Etienne Brain; Aleksandra Dudek-Peric; Miguel Gil-Gil; Patricia Gomez; Florentine S Hilbers; Zaman Khalil; Susan Knox; Sherko Kuemmel; Georg Kunz; Anne Lesur; Jean-Yves Pierga; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Alastair M Thompson; Giuseppe Viale; Gabriele Zoppoli; Peter Vuylsteke; Konstantinos Tryfonidis; Coralie Poncet; Jan Bogaerts; Fatima Cardoso Journal: J Clin Oncol Date: 2020-02-21 Impact factor: 44.544
Authors: Philip D Poorvu; Shari I Gelber; Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Laura C Collins; Jeffrey Peppercorn; Lidia Schapira; Virginia F Borges; Steven E Come; Ellen Warner; Debbie M Jakubowski; Christy Russell; Eric P Winer; Ann H Partridge Journal: J Clin Oncol Date: 2019-12-06 Impact factor: 44.544
Authors: Julian Puppe; Tabea Seifert; Christian Eichler; Henryk Pilch; Peter Mallmann; Wolfram Malter Journal: Breast Care (Basel) Date: 2020-07-21 Impact factor: 2.860